...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Amelioration of human allograft arterial injury by atorvastatin or simvastatin correlates with reduction of interferon-gamma production by infiltrating T cells.
【24h】

Amelioration of human allograft arterial injury by atorvastatin or simvastatin correlates with reduction of interferon-gamma production by infiltrating T cells.

机译:阿托伐他汀或辛伐他汀对同种异体移植动脉损伤的缓解作用与通过浸润T细胞减少γ-干扰素产生有关。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Graft arteriosclerosis (GA) is an important factor limiting long-term outcomes after organ transplantation. We have used a chimeric humanized mouse system to model this arteriopathy in human vessels, and found that the morphologic and functional changes of experimental GA are interferon (IFN)-gamma dependent. This study evaluated whether 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, described as inhibitors of IFN-gamma production, affect GA in our model. METHODS: C.B.-17 severe combined immunodeficiency-beige mice were transplanted with human artery segments as aortic interposition grafts and inoculated with allogeneic human peripheral blood mononuclear cells (PBMCs) or replication-deficient adenovirus encoding human IFN-gamma. Transplant arteries were analyzed from recipients treated with vehicle vs. atorvastatin or simvastatin at different doses. The effects of statins on T-cell alloresponses to vascular endothelial cells were also investigated in vitro. RESULTS: Graft arteriosclerosis-like arteriopathy induced by PBMCs was reduced by atorvastatin at 30 mg/kg/day or simvastatin at 100 mg/kg/day that correlated with decreased graft-infiltrating CD3+ T cells. Circulating IFN-gamma was also reduced, as were graft IFN-gamma and IFN-gamma-inducible chemokine transcripts and graft human leukocyte antigen-DR expression. Graft arteriosclerosis directly induced by human IFN-gamma in the absence of human PBMCs was also reduced by atorvastatin, but only at the highest dose of 100 mg/kg/day. Finally, atorvastatin decreased the clonal expansion and production of interleukin-2, but not IFN-gamma, by human CD4+ T cells in response to allogeneic endothelial cells in coculture. CONCLUSIONS: Our results suggest that a benefit of statin administration in transplantation may include amelioration of GA primarily by inhibiting alloreactive T-cell accumulation and consequent IFN-gamma production and secondarily through suppression of the arterial response to IFN-gamma.
机译:背景:动脉粥样硬化(GA)是限制器官移植后长期结果的重要因素。我们已经使用嵌合的人源化小鼠系统来模拟人类血管中的这种动脉病变,并且发现实验性GA的形态和功能变化是干扰素(IFN)-γ依赖性的。这项研究评估了被称为IFN-γ产生抑制剂的3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂是否会影响我们模型中的GA。方法:将C.B.-17重度联合免疫缺陷-米色小鼠作为人动脉段移植物植入人动脉段,并接种同种异体人外周血单个核细胞(PBMC)或编码人IFN-γ的复制缺陷型腺病毒。分析了接受媒介物与阿托伐他汀或辛伐他汀不同剂量治疗的受体的移植动脉。他汀类药物对T细胞对血管内皮细胞的过敏反应的影响也进行了体外研究。结果:阿托伐他汀(30 mg / kg / day)或辛伐他汀(100 mg / kg / day)减少了PBMC诱导的移植物样动脉硬化样动脉病,这与移植物浸润的CD3 + T细胞减少有关。循环IFN-γ也降低,移植IFN-γ和IFN-γ诱导的趋化因子转录本和移植人白细胞抗原-DR表达也降低。阿托伐他汀也可在无人PBMC的情况下直接由人IFN-γ诱导的移植物动脉硬化,但仅限于最高剂量100 mg / kg / day。最后,阿托伐他汀降低了人类CD4 + T细胞在共培养过程中对同种异体内皮细胞的响应,从而降低了白细胞介素2(而非IFN-γ)的克隆扩增和产生。结论:我们的结果表明,他汀类药物在移植中的益处可能包括改善GA,首先是通过抑制同种反应性T细胞积聚和随后的IFN-γ产生,其次是通过抑制动脉对IFN-γ的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号